Plus Therapeutics Inc. (PSTV)
0.74
-0.05 (-5.98%)
At close: Apr 11, 2025, 1:20 PM
Plus Therapeutics Revenue Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Sep 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 |
|---|---|---|---|---|---|---|
| Grant Revenue | 1.46M | 1.28M | 1.24M | 506K | 151K | 73K |
| Grant Revenue Growth | +13.84% | +3.15% | +145.06% | +235.10% | +106.85% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 |
|---|---|---|---|---|
| Americas Revenue | 293K | 345K | 936K | 787K |
| Americas Revenue Growth | -15.07% | -63.14% | +18.93% | n/a |
| Asia Pacific Revenue | 50K | 76K | 62K | 2.39M |
| Asia Pacific Revenue Growth | -34.21% | +22.58% | -97.41% | n/a |
| E M E A Revenue | 270K | 344K | 379K | n/a |
| E M E A Revenue Growth | -21.51% | -9.23% | n/a | n/a |
| Japan Revenue | 2.06M | 1.92M | 3.28M | n/a |
| Japan Revenue Growth | +6.96% | -41.32% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 2.4M | 2.2M | 2.03M | 2.2M | 2M | 1.92M | 2.24M | 3.58M | 2.22M | 2.29M | 2.14M | 2.04M | 1.99M | 1.47M | 1.35M | 2.3M | 1.06M | 1.43M | 1.62M | 1.67M | 1.17M | 972K | 1.94M | 1.5M | 1.94M | 1.99M | 2.92M | 2.13M | 2.63M | 3.38M | 3.05M | 2.81M | 2.83M | 3.22M | 3.32M | 2.71M | 2.94M | 3.45M | 3.34M |
| Selling, General, and Administrative Revenue Growth | +8.81% | +8.68% | -7.74% | +9.96% | +3.85% | -14.22% | -37.43% | +61.34% | -2.93% | +6.91% | +4.85% | +2.61% | +35.47% | +8.65% | -41.19% | +116.89% | -25.82% | -11.68% | -3.23% | +42.91% | +20.37% | -49.79% | +28.89% | -22.54% | -2.76% | -31.76% | +37.05% | -18.78% | -22.38% | +10.99% | +8.51% | -0.74% | -12.06% | -3.13% | +22.68% | -7.80% | -14.82% | +3.27% | n/a |
| Research and Development Revenue | 2.86M | 2.77M | 2.76M | 2.79M | 2.49M | 1.42M | 2.98M | 2.14M | 2.94M | 2.83M | 1.78M | 1.85M | 1.49M | 1.11M | 1.13M | 1.1M | 336K | 1.11M | 941K | 1.73M | 921K | 1.29M | 1.85M | 2.26M | 1.92M | 1.95M | 2.5M | 2.39M | 3M | 2.99M | 4.97M | 2.86M | 3.96M | 5.25M | 4.13M | 4.63M | 4.35M | 6.05M | 3.96M |
| Research and Development Revenue Growth | +3.07% | +0.36% | -1.11% | +12.07% | +75.56% | -52.40% | +39.52% | -27.40% | +4.03% | +58.60% | -3.46% | +24.01% | +34.81% | -1.86% | +2.83% | +226.19% | -69.68% | +17.75% | -45.58% | +87.73% | -28.55% | -30.17% | -18.17% | +17.75% | -1.79% | -21.93% | +4.39% | -20.31% | +0.40% | -39.86% | +73.83% | -27.73% | -24.53% | +27.14% | -10.84% | +6.36% | -28.04% | +52.61% | n/a |